ArriVent BioPharma, Inc. (AVBP) › Cash & EquivalentsArriVent BioPharma, Inc. (AVBP) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2023: $150.39M2024: $74.29M2025: $45.54M$45.54M2023Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$45.54M-38.7%2024$74.29M-50.6%2023$150.39M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share